- Cardiac Electrophysiology Key Opinions
Leaders to include Paul Dorian, MD,
and Jonathan Piccini, MD
- Conference call and webcast on
Monday, May 22, 2023 at 8:00 a.m. ET
MONTREAL and CHARLOTTE, N.C., May 8, 2023
/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST),
a biopharmaceutical company focused on the development and
commercialization of innovative cardiovascular medicines, today
announced that the Company will host a virtual Key Opinion Leader
(KOL) event on Monday, May 22, 2023
at 8:00 a.m. ET. The event will focus
on etripamil, the Company's lead investigational product, for the
potential treatment of patients with atrial fibrillation (AFib) and
rapid ventricular rate (AFib-RVR).
The event will feature a review of data from a subset of
patients with AFib-RVR in the NODE-303 study, being presented
during an oral session at the upcoming Heart Rhythm 2023 Annual
Meeting. Also featured at this KOL event will be an overview of
AFib-RVR, the current treatment landscape, characteristics of
etripamil, and commentary on next steps for Milestone's etripamil
clinical development program for AFib-RVR. Joining Milestone's
management team will be:
- Paul Dorian, MD, MSC, Professor
of Medicine, Departments of Medicine and Pharmacology, University
of Toronto; Staff Cardiac Electrophysiologist, St. Michael's Hospital
- Jonathan P. Piccini, MD, MHS,
Professor of Medicine, Director of Cardiac Electrophysiology,
Duke University School of Medicine
To access a live or recorded webcast of the event and
accompanying slides, please visit the News & Events section of
Milestone's website at www.milestonepharma.com. To access the
live call by phone, dial (877) 870-4263 (domestic) or (412)
317-0790 (international) and ask to be connected to the Milestone
Pharmaceuticals call. The recorded webcast and slides will be
available on the Company's website following the call.
About Atrial Fibrillation with Rapid Ventricular Rate
Atrial fibrillation (AFib) is a common arrhythmia marked by an
irregular and often rapid heartbeat. AFib is estimated to affect
five million patients in the United
States, a prevalence projected by the Centers for Disease
Control to increase to twelve million patients by 2030. Atrial
fibrillation with rapid ventricular rate (AFib-RVR) is a condition
that many patients with AFib experience and includes episodes of
abnormally high heart rate, often with symptoms of palpitations,
shortness of breath, dizziness, and weakness. Oral calcium channel
blockers and/or beta blockers are used to reduce the heart rate in
this condition. When AFib-RVR occurs, symptoms are often burdensome
enough to cause patients to seek acute care in the emergency
department, where standard-of-care procedures include intravenous
administration of calcium channel blockers or beta blockers, or
electrical cardioversion, under medical supervision. Milestone's
initial market research indicates that 30-40% of patients with AFib
experience one or more symptomatic episodes of RVR per year that
require treatment, suggesting a target addressable market of
approximately three to four million patients in 2030 for etripamil
in patients with AFib.
About Etripamil
Etripamil, Milestone's lead investigational product, is a novel
calcium channel blocker nasal spray. It is designed to be a
rapid-response therapy that is self-administered by the patient,
without the need for direct medical oversight, for elevated and
often highly symptomatic heart rate attacks associated with PSVT
and AFib-RVR. If approved, etripamil is intended to provide health
care providers with a new tool to enable virtual care and patient
self-management, and to impart upon the patient a greater sense of
control over their condition. Milestone is conducting a
comprehensive development program for etripamil, with Phase 3
trials completed and a new drug application (NDA) soon to be
submitted in the third quarter of 2023 in paroxysmal
supraventricular tachycardia (PSVT). Milestone also has a Phase 2
proof-of-concept trial that is ongoing in patients with atrial
fibrillation with rapid ventricular rate (AFib-RVR).
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a
biopharmaceutical company focused on the development and
commercialization of innovative cardiovascular medicines.
Milestone's lead product candidate etripamil recently completed its
Phase 3 clinical-stage program for the treatment of paroxysmal
supraventricular tachycardia (PSVT) and is in a Phase 2
proof-of-concept trial for the treatment of patients with atrial
fibrillation with rapid ventricular rate (AFib-RVR). Milestone
Pharmaceuticals operates in Canada
and the United States. For more
information, visit www.milestonepharma.com and follow Milestone on
Twitter at @MilestonePharma.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "believe," "continue," "could," "demonstrate,"
"designed," "develop," "estimate," "expect," "may," "pending,"
"plan," "potential," "progress," "will" and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. These forward-looking statements are
based on Milestone's expectations and assumptions as of the date of
this press release. Each of these forward-looking statements
involves risks and uncertainties. Actual results may differ
materially from these forward-looking statements. Forward-looking
statements contained in this press release include statements
regarding Milestone's plans to submit an NDA in the third quarter
of 2023. Important factors that could cause actual results to
differ materially from those in the forward-looking statements
include, but are not limited to, the risks inherent in
biopharmaceutical product development and clinical trials,
including the lengthy and uncertain regulatory approval process;
uncertainties related to the timing of initiation, enrollment,
completion, evaluation and results of our clinical trials; risks
and uncertainty related to the complexity inherent in cleaning,
verifying and analyzing trial data; and whether the clinical trials
will validate the safety and efficacy of etripamil for PSVT or
other indications, among others, general economic, political, and
market conditions, including deteriorating market conditions due to
investor concerns regarding inflation and Russian hostilities in
Ukraine and overall fluctuations
in the financial markets in the United
States and abroad, risks related to pandemics and public
health emergencies, and risks related the sufficiency of
Milestone's capital resources and its ability to raise additional
capital in the current economic climate. These and other risks are
set forth in Milestone's filings with the U.S. Securities and
Exchange Commission, including in its annual report on Form 10-K
for the year ended December 31, 2022,
under the caption "Risk Factors," as such discussion may be updated
from time to time by subsequent filings we may make with the U.S.
Securities & Exchange Commission. Except as required by law,
Milestone assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
Contact
David Pitts
Argot Partners
212-600-1902
milestone@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-host-virtual-key-opinion-leader-event-on-etripamil-for-the-treatment-of-atrial-fibrillation-with-rapid-ventricular-rate-301817791.html
SOURCE Milestone Pharmaceuticals, Inc.